Clinical Trial Update: Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluated Polydeoxyribonucleotide (Placentex Mastelli, Pdrn) for the treatment of diabetic ulcers. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer
• Diabetic Ulcer

Drugs mentioned

• Placentex Mastelli (Pdrn) (polydeoxyribonucleotide)

Snippet

Sponsor: University of Messina | Conditions: Diabetic Ulcer, Foot Ulcer Unhealed | Phase 4 | Status: COMPLETED